Allarity Therapeutics Announces Expansion to Proteomics & Cell Line Research

What Happened

• On September 28, 2026 Allarity Therapeutics, Inc. (ALLR) announced it is expanding its in‑house medical laboratory capabilities to include proteomics and cell line research. The company filed a Form 8‑K reporting this event on September 29, 2026 and attached a press release as Exhibit 99.1.

Key Details

• Announcement date: September 28, 2026; Form 8‑K filed September 29, 2026.
• New capabilities: proteomics (protein analysis) and cell line research added to the company’s in‑house lab.
• Disclosure: the update was issued via a press release included as Exhibit 99.1 to the 8‑K.
• The 8‑K does not provide financial impacts, timelines, or detailed operational metrics.

Why It Matters

• This is an operational update showing Allarity is building internal laboratory capacity for advanced protein and cell-based work. For investors, the filing confirms a strategic step in R&D infrastructure, but it does not include costs, expected benefits, or schedule. Monitor future filings or company releases for details on how the expansion affects development programs, budgets, or timelines.